Go to
JCI Insight
Citations to this article
Sharlene M. Day, … , Jil C. Tardiff, E. Michael Ostap
Published March 1, 2022
Citation Information: J Clin Invest. 2022;132(5):e148557. https://doi.org/10.1172/JCI148557.
Citation Information: J Clin Invest. 2022;132(5):e148557. https://doi.org/10.1172/JCI148557.
Abstract
Myosin modulators are a novel class of pharmaceutical agents that are being developed to treat patients with a range of cardiomyopathies. The therapeutic goal of these drugs is to target cardiac myosins directly to modulate contractility and cardiac power output to alleviate symptoms that lead to heart failure and arrhythmias, without altering calcium signaling. In this Review, we discuss two classes of drugs that have been developed to either activate (omecamtiv mecarbil) or inhibit (mavacamten) cardiac contractility by binding to β-cardiac myosin (MYH7). We discuss progress in understanding the mechanisms by which the drugs alter myosin mechanochemistry, and we provide an appraisal of the results from clinical trials of these drugs, with consideration for the importance of disease heterogeneity and genetic etiology for predicting treatment benefit.
Authors
Sharlene M. Day, Jil C. Tardiff, E. Michael Ostap
Citation information
Citations to this article (37)
| Title and authors | Publication | Year |
|---|---|---|
|
Mavacamten inhibits myosin activity by stabilising the myosin interacting-heads motif and stalling motor force generation
McMillan SN, Pitts JR, Barua B, Winkelmann DA, Scarff CA |
bioRxiv | 2025 |
|
Phosphorylation of CRYAB induces a condensatopathy to worsen post–myocardial infarction left ventricular remodeling
Islam M, Rawnsley DR, Ma X, Navid W, Zhao C, Guan X, Foroughi L, Murphy JT, Navid H, Weinheimer CJ, Kovacs A, Nigro J, Diwan A, Chang RP, Kumari M, Young ME, Razani B, Margulies KB, Abdellatif M, Sedej S, Javaheri A, Covey DF, Mani K, Diwan A |
The Journal of Clinical Investigation | 2025 |
|
cMyBP-C in hypertrophic cardiomyopathy: gene therapy and small-molecule innovations
Wood PT, Seffrood MM, Colson BA, Stelzer JE |
Frontiers in Cardiovascular Medicine | 2025 |
|
The Genetic Basis of Sudden Cardiac Death: From Diagnosis to Emerging Genetic Therapies.
Dewars ER, Landstrom AP |
Annual review of medicine | 2025 |
|
The role of the troponin T interactions with actin in regulation of cardiac thin filament revealed by the troponin T pathogenic variant Ile79Asn
Risi CM, Landim-Vieira M, Belknap B, Bryant Chase P, Pinto JR, Galkin VE |
Journal of molecular and cellular cardiology | 2025 |
|
The folding of myosin molecules enhances their solubility and mobility within cardiac muscle sarcomeres
Colleen M Kelly, Jody Martin, Michael Previs |
JCI Insight | 2024 |
|
Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future
Zhou S, Liu Y, Huang X, Wu C, Pórszász R |
Frontiers in Cardiovascular Medicine | 2024 |
|
The Expansion of Genetic Testing in Cardiovascular Medicine: Preparing the Cardiology Community for the Changing Landscape.
Reza N, Alford RL, Belmont JW, Marston N |
Current Cardiology Reports | 2024 |
|
Emerging Concepts of Mechanisms Controlling Cardiac Tension: Focus on Familial Dilated Cardiomyopathy (DCM) and Sarcomere-Directed Therapies.
Solaro RJ, Goldspink PH, Wolska BM |
Biomedicines | 2024 |
|
Myosin-Catalyzed ATP Hydrolysis in the Presence of Disease-Causing Mutations: Mavacamten as a Way to Repair Mechanism
Chakraborti A, Tardiff JC, Schwartz SD |
The journal of physical chemistry. B | 2024 |
|
Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction
Auguin D, Robert-Paganin J, Réty S, Kikuti C, David A, Theumer G, Schmidt AW, Knölker HJ, Houdusse A |
Nature Communications | 2024 |
|
Mechanisms of a novel regulatory light chain-dependent cardiac myosin inhibitor.
Kooiker K, Gan QF, Yu M, Sa N, Mohran S, Cheng Y, Flint G, Neys S, Gao C, Nissen D, McMillen T, Asencio A, Ma W, Irving TC, Moussavi-Harami F, Regnier M |
The Journal of general physiology | 2024 |
|
Reassessing the unifying hypothesis for hypercontractility caused by myosin mutations in hypertrophic cardiomyopathy.
Spudich JA, Nandwani N, Robert-Paganin J, Houdusse A, Ruppel KM |
The EMBO journal | 2024 |
|
Myosin Isoform-Dependent Effect of Omecamtiv Mecarbil on the Regulation of Force Generation in Human Cardiac Muscle
Scellini B, Piroddi N, Dente M, Pioner JM, Ferrantini C, Poggesi C, Tesi C |
International Journal of Molecular Sciences | 2024 |
|
Subcellular mass spectrometric detection unveils hyperglycemic memory in the diabetic heart.
Zhan J, Zhou Y, Chen Y, Jin K, Chen Z, Chen C, Li H, Wang DW |
Journal of diabetes | 2024 |
|
Miocardiopatias em Crianças e Adolescentes na Era da Medicina de Precisão
Torbey AF, Couto RG, Grippa A, Maia EC, Miranda SA, dos Santos MA, Peres ET, Costa OP, de Oliveira EM, Mesquita ET |
Arquivos Brasileiros de Cardiologia | 2024 |
|
Probing actin‐activated ATP turnover kinetics of human cardiac myosin II by single molecule fluorescence
Berg A, Velayuthan LP, Tågerud S, Ušaj M, Månsson A |
Cytoskeleton (Hoboken, N.j.) | 2024 |
|
Pharmacodynamics of single-dose omecamtiv mecarbil administered intravenously in clinically healthy cats
Ishizaka M, Hsu HH, Miyagawa Y, Takemura N |
Open Veterinary Journal | 2024 |
|
Development and prevention of ischemic contracture (“stone heart”) in the pig heart
Li M, Qin Z, Steen E, Terry A, Wang B, Wohlfart B, Steen S, Arner A |
Frontiers in Cardiovascular Medicine | 2023 |
|
Familial Hypertrophic Cardiomyopathy: Diagnosis and Management
Litt MJ, Ali A, Reza N |
Vascular Health and Risk Management | 2023 |
|
Muscle Mechanics and Thick Filament Activation: An Emerging Two-Way Interaction for the Vertebrate Striated Muscle Fine Regulation
Marcucci L |
International journal of molecular sciences | 2023 |
|
Binding pocket dynamics along the recovery stroke of human β-cardiac myosin.
Akter F, Ochala J, Fornili A |
PLoS computational biology | 2023 |
|
Preserving mitochondria to treat hypertrophic cardiomyopathy: From rare mitochondrial DNA mutation to heart failure therapy?
Abhinav Diwan |
Journal of Clinical Investigation | 2023 |
|
Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets
Correale M, Tricarico L, Croella F, Alfieri S, Fioretti F, Brunetti ND, Inciardi RM, Nodari S |
Frontiers in Cardiovascular Medicine | 2023 |
|
Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin
Hitsumoto T, Tsukamoto O, Matsuoka K, Li J, Liu L, Kuramoto Y, Higo S, Ogawa S, Fujino N, Yoshida S, Kioka H, Kato H, Hakui H, Saito Y, Okamoto C, Inoue H, Hyejin J, Ueda K, Segawa T, Nishimura S, Asano Y, Asanuma H, Tani A, Imamura R, Komagawa S, Kanai T, Takamura M, Sakata Y, Kitakaze M, Haruta JI, Takashima S |
Circulation | 2023 |
|
Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design.
Moussaoui D, Robblee JP, Robert-Paganin J, Auguin D, Fisher F, Fagnant PM, Macfarlane JE, Schaletzky J, Wehri E, Mueller-Dieckmann C, Baum J, Trybus KM, Houdusse A |
Nature Communications | 2023 |
|
Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Sebastian SA, Padda I, Lehr EJ, Johal G |
American journal of cardiovascular drugs : drugs, devices, and other interventions | 2023 |
|
Mouse Models of Cardiomyopathies Caused by Mutations in Troponin C
Tikunova SB, Thuma J, Davis JP |
International journal of molecular sciences | 2023 |
|
Lactylation regulates cardiac function
Ghosh-Choudhary S, Finkel T |
Cell Research | 2023 |
|
Discovery of a novel cardiac-specific myosin modulator using artificial intelligence-based virtual screening
Parijat P, Attili S, Hoare Z, Shattock M, Kenyon V, Kampourakis T |
Nature Communications | 2023 |
|
Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite antagonistic effects in heart contraction
Auguin D, Robert-Paganin J, Réty S, Kikuti C, David A, Theumer G, Schmidt AW, Knölker HJ, Houdusse A |
2023 | |
|
Functional assays reveal the pathogenic mechanism of a de novo tropomyosin variant identified in patient with dilated cardiomyopathy.
Barrick SK, Garg A, Greenberg L, Zhang S, Lin CY, Stitziel NO, Greenberg MJ |
Journal of Molecular and Cellular Cardiology | 2023 |
|
The Interventricular Septum: Structure, Function, Dysfunction, and Diseases
Triposkiadis F, Xanthopoulos A, Boudoulas KD, Giamouzis G, Boudoulas H, Skoularigis J |
Journal of Clinical Medicine | 2022 |
|
Cardiac Sarcomere Signaling in Health and Disease
Martin AA, Thompson BR, Hahn D, Angulski AB, Hosny N, Cohen H, Metzger JM |
International journal of molecular sciences | 2022 |
|
The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications
Ráduly AP, Sárkány F, Kovács MB, Bernát B, Juhász B, Szilvássy Z, Porszász R, Horváth B, Szentandrássy N, Nánási P, Csanádi Z, Édes I, Tóth A, Papp Z, Priksz D, Borbély A |
International journal of molecular sciences | 2022 |
|
Comparative study of binding pocket structure and dynamics in cardiac and skeletal myosin
Antonovic AK, Ochala J, Fornili A |
Biophysical Journal | 2022 |
|
Insights into the Mechanism of the Cardiac Drug Omecamtiv Mecarbil—A Computational Study
Chakraborti A, Tardiff JC, Schwartz SD |
The journal of physical chemistry. B | 2022 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)